Slone Partners

About Us

With a dedicated focus on the life sciences and healthcare industries, Slone Partners is a premier executive search and talent advisory firm with more than 25 years of success delivering visionary leaders and fractional talent who build and scale amazing organizations. With a nationwide presence and global reach, we specialize in discovering and placing innovative leaders, including world-class Board, C-Suite, and upper management professionals.

 

ACHIEVEMENTS

Recent Placements

Slone Partners

Leadership

6

Our leadership is deeply embedded in the industry and supported by an Advisory Board of experts from every sector that we serve.

Staying at the cutting edge of every change in the market allows us to deliver the right candidates for your business and provide invaluable counsel no matter how unique your needs.

Slone Partners

Solutions And Expertise

Founded in 2000, Slone Partners is a premier executive search firm that specializes in recruitment for companies focused in biotechnology, pharma services, life science tools, diagnostics, genomics, clinical services, medical devices, data and analytics, and food sciences.

Solutions
  • Board/Director Search
  • Executive Recruitment
  • Executive Search
  • Fractional
  • Fractional and Interim Services
  • Fractional Executive
  • On-Demand Recruiting
  • On-Demand Talent Solutions
  • Professional Search
Industries
  • Biotechnology
  • Executive Search
  • Healthcare
  • Healthcare Services
  • Healthtech
  • Hospital Foundations
  • Life Sciences
  • Life Sci./Healthcare
  • Medical Devices
  • Pharmaceuticals
  • Science and Research
Functions
  • Board Members
  • Board of Directors
  • Business Leaders
  • C-Level
  • C-Level Leaders
  • C-Suite
  • Clinical Directors
  • Clinical Operations
  • Director/VP
  • General Counsel
  • Head of Department
  • Healthcare
  • Healthcare Board Placements
  • President
  • SVP
  • Vice President

Slone Partners

News Briefings

Slone Partners Adds Branding Leadership Expert to Advisory Board

Sumitovant Biopharma executive Mary Stutts has joined the advisory board of executive search firm Slone Partners. Ms. Stutts is a renowned C-level global branding and growth expert who has provided strategic counsel in the biotechnology, healthcare, technology, and media industries at Fortune 200 companies including Genentech, Bayer, Bristol Myers Squibb, Kaiser Permanente, UnitedHealth Group, and Comcast

Slone Partners Recruits CEO for Mesa Biotech

Executive search firm  Slone Partners has recruited Ingo Chakravarty as the new president and CEO of Mesa Biotech. He assumes leadership of the company less than two months after it received emergency use authorization from the Federal Drug Administration to market its 30-minute point-of-care molecular SARS-CoV-2 test. Mr. Chakravarty succeeds Dr. Hong Cai, co-founder and CEO of Mesa Biotech since

Slone Partners Secures Chief Medical Officer of OmniSeg

Executive search firm Slone Partners has placed Roger D. Klein as chief medical officer of OmniSeq. Dr. Klein will support OmniSeq in its continued development of innovative products that help oncologists identify the best precision medicine options for their patients. “Dr. Klein is a highly accomplished leader in the innovative fields of molecular pathology, oncology and precision medicine,” said

CEO Confidence Falls to Lowest Levels Since 2008 Great Recession

Amid the fallout from COVID-19, confidence among U.S. CEOs has declined sharply. The Conference Board Measure of CEO Confidence decreased from 43 in the fourth quarter of 2019 to 36 in the first quarter of 2020. In addition, a follow-up survey from late March to early April showed a further decline to 34. (A reading of

Slone Partners

Press Releases

Slone Partners Places Susan Landis as Executive Director at the Association of Clinical Research Professionals’ Board of Trustees

(June 2, 2021) Slone Partners, a nationwide executive search firm for life sciences, biotechnology, and diagnostics companies, has announced the placement of Susan Landis as Executive Director of the Association of Clinical Research Professionals’ (ACRP) Board of Trustees. She will begin serving in her new role effective June 14, 2021. Landis brings to ACRP more

Slone Partners Places Sotirios Karathanasis as Chief Science Officer at Enveda Biosciences

(April 29, 2021) Slone Partners, a nationwide executive search firm for life science, biotechnology, and diagnostics companies, has announced the placement of Sotirios Karathanasis, Ph.D. as the new Chief Science Officer (CSO) at Enveda Biosciences. In his new role, Dr. Karathanasis will lead the company’s small molecule drug discovery portfolio and work with Enveda’s preclinical

Slone Partners, Where People Are Our Science®, Places Amol Chaubal as Chief Financial Officer at Quanterix

BOSTON, MA, April 12, 2019 – Slone Partners, North America’s leading executive search firm for life sciences and diagnostics companies, announces the placement of Amol Chaubal at Quanterix Corporation as Chief Financial Officer. Responsible for the strategic and tactical financial health of Quanterix as the precision medicine company executes rapid scaling, Mr. Chaubal will report to

Slone Partners, Where People Are Our Science®, Places Lloyd Sanders As CEO At Epic Sciences, Inc.

SAN FRANCISCO, CA, April 16, 2019 – Slone Partners, North America’s leading executive search firm for life sciences and diagnostics companies, announces the placement of Lloyd Sanders at Epic Sciences, Inc. as Chief Executive Officer. With headquarters in San Diego, California, Mr. Sanders is responsible for all strategic and business aspects of the oncological diagnostics company. Epic Sciences

Slone Partners Places Eric Blair as Chief Commercial Officer at Argonaut Manufacturing Services, Inc.

SAN FRANCISCO – December 5, 2018 – Slone Partners, North America’s leading executive search firm for life sciences and diagnostics companies, announces the placement of Eric Blair at Argonaut Manufacturing Services as Chief Commercial Officer. Now responsible for the development and execution of the company’s commercial activities, alliances, and growth opportunities, Mr. Blair will be based